TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00607334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word-learning
Description: Exposure to five nonwords for three sessions of controlled interaction with the experimenter

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word-learning
Description: Exposure to five nonwords for three sessions of controlled interaction with the experimenter
Study: NCT01870141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention
Description: 1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~* self-monitoring~* problem solving~* goal definition~* cognitive restructuring~* activation of personal and social resources
Study: NCT04179487

Intervention type: DIAGNOSTIC_TEST
Intervention: OPTICA CTPA Protocol
Description: Low dose CT pulmonary angiogram protocol
Study: NCT01650753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Powder
Description: Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10\^10 cells/sachet)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
Study: NCT02815553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Transthoracic Cardiac Tumor Laser Ablation Therapy
Study: NCT00526123

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symmetric Tip Catheter
Description: Dialysis catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Split-tip Catheter
Description: Dialysis Catheter
Study: NCT03273946

Intervention type: DRUG
Intervention: Fluticasone propionate
Description: Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
Study: NCT02638038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT131
Description: INT- 131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT131
Description: INT- 131

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INT131
Description: INT- 131
Study: NCT00687648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given as previously prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given as previously prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given as previously prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Given by mouth
Study: NCT04210817

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT03310151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imagined movements
Description: Imagined wrist movements, 10-15 minutes, 4 times a day.
Study: NCT01913067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Intravenous, 25 mg/m2 every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced whole brain MRI
Description: Evaluation of the volumetric reduction in the size of the brain lesion(s).
Study: NCT04290754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH-IT
Description: Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEAMS
Description: Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
Study: NCT02990819

Intervention type: DEVICE
Group type: OTHER
Intervention: Apha/beta T and CD19+ cell depletion using CliniMACS device
Description: Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.

Intervention type: DEVICE
Group type: OTHER
Intervention: Apha/beta T and CD19+ cell depletion using CliniMACS device
Description: Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.

Intervention type: DEVICE
Group type: OTHER
Intervention: Apha/beta T and CD19+ cell depletion using CliniMACS device
Description: Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
Study: NCT03337529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 200 mg Vitamin C will be given on daily basis for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg placebo will be given on daily basis for 8 weeks
Study: NCT02958969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
Study: NCT03122418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Fitness Device
Description: Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
Study: NCT00887497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioembolization
Description: Angioembolization
Study: NCT01371344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: oral
Study: NCT00885859

Intervention type: DEVICE
Intervention: TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]
Description: Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).

Intervention type: DEVICE
Intervention: TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]
Description: Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
Study: NCT03571347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Help Plus
Description: 5-session psychosocial intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment As Usual
Description: Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
Study: NCT02686359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sample

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sample
Study: NCT01799785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT02160834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-MOBILE Smartphone-Based Intervention (3-min break)
Description: Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-MOBILE Smartphone-Based Intervention (6-min break)
Description: Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time.
Study: NCT00666991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticulate paclitaxel
Description: This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticulate paclitaxel
Description: This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticulate paclitaxel
Description: This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticulate paclitaxel
Description: This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticulate paclitaxel
Description: This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Study: NCT01371344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsules
Description: oral
Study: NCT00666991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticulate paclitaxel
Description: This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Study: NCT00368537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin-sulbactam
Description: Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued.
Study: NCT03458507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Switch of nocturnal NIV interface
Description: 1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~2. Interface switch~3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Switch of nocturnal NIV interface
Description: 1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~2. Interface switch~3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction.
Study: NCT02409173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive airway pressure flow generator device
Description: Noninvasive positive airway pressure flow generator device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Standard Roux-en-Y gastric bypass
Study: NCT02570490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fusidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Study: NCT04482647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View instructional video

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Perform meditation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Perform breathing techniques
Study: NCT02198027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infiltration
Description: 23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
Study: NCT03156049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine block
Description: patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater occipital nerve block
Description: patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
Study: NCT02245152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS
Description: A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child's health and nutrition topics
Description: After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National policy well-baby visits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National policy well-baby visits
Study: NCT01479465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 administered via intravenous infusion over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours
Study: NCT04154787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Investigation of LNP023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Comparison of rituximab dose
Study: NCT01775228

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support
Description: Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
Study: NCT06670183

Intervention type: OTHER
Intervention: Dietary patterns
Description: Dietary patterns such as regular meat-eater, occasional meat-eater, pescatarian, and vegetarian; Mediterranean diet.

Intervention type: OTHER
Intervention: Food groups and Nutrients
Description: Dietary components, such as oily fish, dairy product, supplements, fibre, vitamin D supplements.

Intervention type: OTHER
Intervention: Alcohol intake
Description: Frequency and intake of alcoholic beverages was measured by self-reporting the weekly frequency of different types of alcoholic beverages, e.g., the number of pints of beer/cider consumed per week and measures of spirits or liquors consumed per week were collected to assess consumption of beer/cider and spirits.

Intervention type: OTHER
Intervention: Vitamin D status
Description: Serum 25(OH)D was measured once at baseline through a non-fasted blood draw during any season of the year.
Study: NCT03800823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent group
Description: In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth component
Description: After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for overweight and obesity.
Study: NCT02637206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 Cream
Description: GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 Cream
Description: GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream
Description: Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream
Description: Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empty Patch
Description: Empty patches without any ingredients will be used as negative control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empty Patch
Description: Empty patches without any ingredients will be used as negative control.